Drug Discovery & Pharmaceuticals

RSS

Nanosatellite paves the way for developing RNA-based medicines

Researchers from Aarhus University and Berkeley Laboratory have designed RNA molecules, that folds into nanoscale rectangles, cylinders, and satellites, and have studied their 3D structure and dynamics with advanced nanotechnological methods.

28 Feb 2023

Study shows why a specific gene mutation has opposite effects on mice and human cancers

A small but significant metabolic difference between human and mouse lung tumor cells, has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results, and pointing toward new strategies for developing cancer treatments.

27 Feb 2023

Insilico Medicine: IND application for first generative AI-designed drug for COVID-19 approved

Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico's proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

24 Feb 2023

Prototype treatment shows great potential in neutralizing snake toxins from multiple species

Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.

24 Feb 2023

New puzzle challenge taps into the intelligence of Eterna’s users to advance RNA therapeutics

Researchers at UC Santa Cruz working to develop novel RNA-based medicines are teaming up with a new group of collaborators-;players of the online game Eterna.

22 Feb 2023

Reimagining FDA-approved drugs for spinocerebellar ataxia type 5

A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.

17 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform.

From Inventia Life Science 16 Feb 2023

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Extracts from two common wild plants block SARS-CoV-2 from entering human cells

Two common wild plants contain extracts that inhibit the ability of the virus that causes COVID-19 to infect living cells, an Emory University study finds.

13 Feb 2023

Novel method enables targeted design of molecules and materials with specific properties

Engineering novel molecules and materials with specific properties can yield significant advances for industrial processes, drug discovery and optoelectronics.

9 Feb 2023

Oral difelikefalin could reduce the intensity of itch in patients with notalgia paresthetica

Notalgia paresthetica-;a nerve disorder characterized by a persistent itch in the upper back-;is a common and underdiagnosed condition worldwide.

9 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

Drug Discovery & Pharmaceuticals

Nanosatellite paves the way for developing RNA-based medicines

Study shows why a specific gene mutation has opposite effects on mice and human cancers

Insilico Medicine: IND application for first generative AI-designed drug for COVID-19 approved

Prototype treatment shows great potential in neutralizing snake toxins from multiple species

New puzzle challenge taps into the intelligence of Eterna’s users to advance RNA therapeutics

Reimagining FDA-approved drugs for spinocerebellar ataxia type 5

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

Extracts from two common wild plants block SARS-CoV-2 from entering human cells

Novel method enables targeted design of molecules and materials with specific properties

Oral difelikefalin could reduce the intensity of itch in patients with notalgia paresthetica

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Novel combination therapy shows promise in acute myeloid leukemia

Gaining insights into human disease biology through CRISPR platforms

Antibody that blocks VEGF-B could be a potential therapeutic option for fatty liver disease

New chemical reaction could transform drug production

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Clinically approved fungal vaccine protects against fungal infections

Scientists develop new design principles to improve cancer vaccines

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics